|
Urinary tract infection
|
0.100 |
Biomarker
|
group |
BEFREE |
However, potential concerns of SGLT2 inhibition include volume depletion and urinary tract infections.
|
31437852 |
2019 |
|
Urinary tract infection
|
0.100 |
Biomarker
|
group |
BEFREE |
They reported 19 patients with life-threatening sepsis due to UTI and severe pyelonephritis after initiating SGLT-2 inhibitors who required hospitalization.
|
31763787 |
2019 |
|
Urinary tract infection
|
0.100 |
Biomarker
|
group |
BEFREE |
When compared with placebo, SGLT2 inhibitors were found to be significantly protective against AKI (RR=0.59; 95% CI 0.39 to 0.89; I<sup>2</sup>=0.0%), while no difference was found for DKA (RR 0.66; 95% CI 0.30 to 1.45, I<sup>2</sup>=0.0%), UTI (RR 1.02; 95% CI 0.95 to 1.09, I<sup>2</sup>=0.0%) or bone fracture (RR 0.87; 95% CI 0.69 to 1.09, I<sup>2</sup>=1.3%).
|
30813108 |
2019 |
|
Urinary tract infection
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Incident use of SGLT2 inhibitors among older women and men is associated with increased risk of genital mycotic infections within 30 days; there is no associated increased risk of UTI.
|
31264755 |
2019 |
|
Urinary tract infection
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 receptor (GLP-1) agonists.
|
31357213 |
2019 |
|
Urinary tract infection
|
0.100 |
Biomarker
|
group |
BEFREE |
The risk of urinary tract infection (UTI) was not increased with SGLT-2 inhibitors compared to placebo (RR 1.03, 95% CI 0.96-1.11, I<sup>2</sup> 0%) or active comparator (RR 1.08, 95% CI 0.93-1.25, I<sup>2</sup> 22%).
|
29484489 |
2018 |
|
Urinary tract infection
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2 inhibitors may have little or no effect on the risk of cardiovascular death, hypoglycaemia, acute kidney injury (AKI), and urinary tract infection (low certainty evidence).
|
30246878 |
2018 |
|
Urinary tract infection
|
0.100 |
Biomarker
|
group |
BEFREE |
In the patients with T2D and moderate renal function impairment (30 ml/min/1.73 m<sup>2</sup> ≤ estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m<sup>2</sup>) compared with the placebo, SGLT2 inhibitors improved HbA1c significantly (WMD, -0.23%; 95% CI: -0.38 to -0.08), presented a lower incidence of hypoglycemia (30.1% vs. 34.6%; RR, 0.85; 95% CI: 0.76 to 0.96), led to the reduction of eGFR (WMD, -1.74 ml/min/1.73 m<sup>2</sup>; 95% CI: -3.45 to -0.03), resulted in an obvious reduction in body weight (WMD, -1.45 kg; 95% CI: -2.01 to -0.89), and presented a similar risk of urinary tract infection and genital infection.
|
29649541 |
2018 |
|
Urinary tract infection
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This case suggests there may be an increased risk of UTI in patients prescribed SGLT2 inhibitors who also have evidence of bladder outlet obstruction-caution is advised in the prescribing of SGLT2 inhibitors in this setting.
|
28536217 |
2017 |
|
Urinary tract infection
|
0.100 |
GeneticVariation
|
group |
BEFREE |
30) and urinary tract infection (UTI) (OR 1.34, 95%CI [0.79, 2.27], P = .28) were proved as no difference and genital tract infection (GTI) with SGLT2 inhibitors was higher than control group (OR 2.96, 95%CI [1.05, 8.37], P = .04), in which cases were mild and responded to the therapy.
|
28538386 |
2017 |
|
Urinary tract infection
|
0.100 |
Biomarker
|
group |
BEFREE |
The meta-analyses of randomized controlled trials (RCTs) showed no significant difference in UTIs between SGLT2 inhibitors versus control (2,526/29,086 vs. 1,278/14,940; risk ratio (RR) 1.05, 95% confidence interval (CI) 0.98 to 1.12; moderate quality evidence), but suggested increased risk of genital infections with SGLT2 inhibitors (1,521/24,017 vs. 216/12,552; RR 3.30, 95% CI 2.74 to 3.99; moderate quality evidence).
|
28588220 |
2017 |
|
Urinary tract infection
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We systematically searched PubMed, Embase, CENTRAL, and ClinicalTrials.gov from inception to October 9, 2016 to identify randomized controlled trials (RCTs) reporting the occurrence of UTIs and genital infections in patients with T2DM treated with SGLT2 inhibitors.
|
27862830 |
2017 |